Cosibelimab

柯希利单抗

Report date: 2025/06/12 15:42:58

Base Information

Drug NameCosibelimab
Drug Alias Namecosibelimab-ipdlUNLOXCYUnloxcytUNLOXCITTG-1501 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[13] 
Global Approved IndicationsCarcinoma, Squamous Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/12/13
Country/TerritoryUnited StatesUkrainePoland +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesTg Therapeutics IncCheckpoint Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG